X4 Pharmaceuticals Inc [XFOR] stock prices are down -3.52% to $3.84 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The XFOR shares have gain 21.90% over the last week, with a monthly amount glided 9.56%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, B. Riley Securities downgraded its rating to Neutral on December 12, 2023, and dropped its price target to $1. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $3 on December 22, 2022. Piper Sandler initiated its recommendation with a Overweight and recommended $3 as its price target on December 12, 2022. Oppenheimer started tracking with a Outperform rating for this stock on December 23, 2019, and assigned it a price target of $20. In a note dated December 18, 2019, ROTH Capital initiated an Buy rating and provided a target price of $20 on this stock.
The stock price of X4 Pharmaceuticals Inc [XFOR] has been fluctuating between $1.35 and $26.83 over the past year. Currently, Wall Street analysts expect the stock to reach $6.75 within the next 12 months. X4 Pharmaceuticals Inc [NASDAQ: XFOR] shares were valued at $3.84 at the most recent close of the market. An investor can expect a potential return of 75.78% based on the average XFOR price forecast.
Analyzing the XFOR fundamentals
The X4 Pharmaceuticals Inc [NASDAQ:XFOR] reported sales of 33.98M for trailing twelve months, representing a surge of 215.18%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -3.23%, Pretax Profit Margin comes in at -3.1%, and Net Profit Margin reading is -3.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.97, Equity is -3.75 and Total Capital is -1.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.55.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.71 points at the first support level, and at 3.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.96, and for the 2nd resistance point, it is at 4.08.
Ratios To Look Out For
It’s worth pointing out that X4 Pharmaceuticals Inc [NASDAQ:XFOR]’s Current Ratio is 5.65. Also, the Quick Ratio is 5.48, while the Cash Ratio stands at 1.71. Considering the valuation of this stock, the price to sales ratio is 9.88, the price to book ratio is 1.57.
Transactions by insiders
Recent insider trading involved Craig Adam R, Executive Chairman, that happened on Oct 23 ’25 when 86206.0 shares were purchased. Chief Commercial Officer, Baldry Mark completed a deal on May 16 ’25 to buy 1032.0 shares. Meanwhile, President and CEO Ragan Paula sold 76473.0 shares on Jan 24 ’25.
